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Little is known about the impact of human rhinovirus (HRV) and coronavirus infections in hematopoietic
stem cell transplant (HSCT) recipients. We tested bronchoalveolar lavage (BAL) samples obtained from HSCT
recipients with acute pulmonary infiltrates for HRV ( ) and coronavirus ( ) by reverse-transcrip-np 122 np 46
tase polymerase chain reaction. HRV RNA was detected in 6 (8%) of 77 patients, and coronavirus RNA was
detected in 0 of 46 of BAL samples from HSCT recipients. The fatality rate in HRV-infected patients was high
(83%), but all patients had significant coinfections, and the overall mortality rate was not different from that
of patients who were negative for HRV in BAL samples. These results suggest that HRV may be a cause of
lower respiratory tract infections in HSCT recipients and that its detection in BAL samples is associated with
frequent copathogens. Whether the poor prognosis is due to HRV or the copathogen is not clear.
Human rhinovirus (HRV) and coronavirus are the
agents most commonly associated with the common
cold and are generally considered to replicate princi-
pally within the upper respiratory tract (URT) [1]. Most
patients with common colds present with a self-limited
syndrome characterized by nasal obstruction, coryza,
sneezing, sore throat, and cough; fever is very uncom-
mon in immunocompetent adults with rhinoviral colds
[2]. In patients with predisposing conditions, such as
underlying lung disease and compromised immunity,
HRV has been associated with lower respiratory tract
disease, including reports of possible viral pneumonia
in infants, hospitalized elderly persons, and transplant
recipients [3–7]. Rhinoviruses have recently been dem-
onstrated to replicate effectively at core temperature
(37C) [8]. In addition, several studies have recovered
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HRV from the lower airways present in the lower trach-
eobronchial tree [9–17], and replicative-strand rhino-
viral RNA has been detected in situ from bronchial
biopsy samples from patients who had been inoculated
experimentally with rhinovirus [18].
The spectrum of disease and outcomes of infection
with HRV and human coronavirus infections in he-
matopoietic stem cell transplant (HSCT) recipients
have received limited study. Bowden [4] detected HRV
infection by viral culture in 25% of 127 HSCT recipients
with acute respiratory illnesses; all had URT infections,
and only 1 had virus recovered from the lower respi-
ratory tract. In contrast, Ghosh et al. [19] recently
described the clinical course of 22 myelosuppressed
adults, who represented ∼1% of HSCT recipients dur-
ing the period of the study, with HRV infection iden-
tified by viral culture. Of these patients, 7 (32%) de-
veloped fatal pneumonia that was attributed to HRV
infection of the lower airways. HRV was cultured an-
temortem from lower respiratory tract samples in 6
patients (86%). The mean time between the onset of
acute respiratory symptoms and respiratory failure in
these patients was 12 days (range, 3–21 days), and the
duration of viral shedding for these patients was 8 days
(range, 1–18 days). One case report has described
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Days to onset, median (range) NA 151 (4–378)
Age, median years (range) 44 (15–59) 48 (15–57)
Male 40 (56) 2 (33)
Race
White 52 (73) 6 (100)
Hispanic 8 (11) 0
Other 11 (16) 0
Type of transplant
Autologous/syngeneic 8 (11) 0
Matched-related 28 (39) 2 (33)
Mismatched 29 (41) 4 (67)
Chronic GVHD 22 (31) 3 (50)
Dead
3 months after transplantation 29 (41) 2 (33)
12 months after transplantation 47 (66) 3 (50)
NOTE. Data are no. (%) of patients, unless otherwise specified. GVHD,
graft-vs.-host disease; HRV, human rhinovirus; NA, not applicable.
the occurrence of human coronavirus pneumonia in a trans-
plant recipient [20]. This patient developed transient respira-
tory distress, which required intubation, but recovered from
the infection.
To better clarify the prevalence of HRV and human corona-
virus lower respiratory tract involvement in HSCT recipients,
we tested 122 consecutively collected bronchoalveolar lavage
(BAL) samples from 77 patients with acute pulmonary infil-
trates for the presence of HRV and, in a limited subgroup,
human coronavirus RNA by RT-PCR, the most sensitive and
appropriate detection technique currently available for these
pathogens [2].
MATERIALS AND METHODS
Consecutive BAL samples, obtained from HSCT recipients at
the Fred Hutchinson Cancer Research Center (FHCRC; Seattle)
with acute pulmonary infiltrates during one respiratory virus
season, were used for the study. The initial evaluation of the
samples included routine viral, bacterial, fungal, and my-
cobacterial cultures; shell-vial cultures for cytomegalovirus
(CMV) and respiratory syncytial virus (RSV); direct fluorescent
antibody staining for herpesviruses, respiratory viruses, and
Legionella species; and cytologic testing with use of methods
discussed elsewhere [21, 22]. In brief, BAL samples were in-
oculated into human foreskin fibroblast (HFF), A-549, and
rhesus monkey kidney (RMK) cell cultures and maintained for
10 (A-549 and RMK) or 28 days (HFF), all at 35C–37C. Shell-
vial centrifugation cultures were performed using CMV- and
RSV-specific antibodies, according to standard techniques de-
scribed elsewhere [21]. Bacterial, fungal, and mycobacterial cul-
tures used standard methodology in the Clinical Microbiology
Laboratory at FHCRC [22]. Direct fluorescent antibody stain-
ing was performed for CMV, adenovirus, parainfluenza viruses
1–4, influenza viruses A and B, RSV, and Legionella species with
use of pathogen-specific monoclonal antibodies (Bartels) ac-
cording to the manufacturer’s instructions. An aliquot of BAL
sample was kept frozen at70C and subsequently tested under
blinded conditions at the University of Virginia for HRV and
human coronavirus, using RT-PCR by techniques described
elsewhere [23, 24]. Human coronavirus RT-PCR was only done
on the first 46 samples. The detection of amplification products
was done by microplate hybridization according to published
methods, with minor modifications [25]. Patient characteristics
and treatment records were obtained from the electronic data-
base and from patient charts maintained at FHCRC.
RESULTS
Seventy-seven patients with newly diagnosed pulmonary infil-
trates by chest radiograph underwent bronchoscopy with BAL
(a total of 122 samples) during the study period (table 1). No
human coronavirus RNA was detected in 46 samples tested.
Six patients (8%) had HRV RNA detected from 8 (6%) of 122
BAL samples. None of the patients had cultures positive for
HRV, although the culture method was not optimized to grow
HRV. Two patients had 2 samples positive for HRV; the 2 BAL
samples were collected 31 and 44 days apart, respectively. One
patient (3; table 2) was first diagnosed with idiopathic pneu-
monia syndrome by biopsy and BAL and improved with steroid
therapy; the patient then developed a lingual lobe infiltrate that
prompted the second BAL. The other patient (4; table 2) had
persistent pulmonary nodules that did not improve after treat-
ment for RSV; the second BAL revealed Aspergillus nidulans in
addition to HRV. Patients 1 and 3 complained of upper respir-
atory symptoms prior to the onset of respiratory distress, and
patient 4 developed an expiratory wheeze concomitant with the
identification of RSV in her BAL fluid.
Among those positive for HRV RNA, the onset of acute
pulmonary infiltrate averaged 151 days after transplantation
(range, 4–378 days). The onset of HRV infection occurred dur-
ing the first 100 days in only 2 (33%) of the 6 HRV-positive
patients. All of the patients were the recipients of allogeneic
HSCT (4 unrelated mismatched donors and 2 matched-
related). Fifty percent had chronic graft-versus-host disease at
the time of illness onset. None of the HRV-positive BAL spec-
imens grew HRV on routine cell culture. None of the 6 patients
had rhinovirus detected by culture in upper respiratory
secretions.
All of the patients had copathogens detected along with HRV
in their BAL samples (table 2); 1 patient had an initial BAL
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death Cause of death
1, unrelated CML DR 143 Jul 1999 None PIV-3 166 Pneumonia (PIV-3)




3, unrelated CLL DR 11 Apr 1999 Extensive (150) None (idiopathic pneumonia
syndrome)





4, matched-related APML DR 378 Apr 1999 None RSV
409 Aspergillus nidulans 466 Pneumonia
(aspergillus)
5, matched-related AML DR 159 Jan 1999 Extensive (150) PIV-3, Pseudomonas
aeruginosa
Alive
6, unrelated PCL DR 4 Sep 1999 None Aspergillus species 9 Pneumonia
(aspergillus)
NOTE. AML, acute myeloid leukemia; APML, acute promyelocytic leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CMV,
cytomegalovirus; D, donor; GVHD, graft-versus-host disease; PCL, plasma cell leukemia; PIV-3, parainfluenzavirus 3; R, recipient; RSV, respiratory syncytial virus;
, positive; , negative.
specimen that grew only HRV and a subsequent BAL 44 days
later that grew both HRV and Aspergillus niger. The most frequent
copathogens were Aspergillus species from 3 patients, parain-
fluenza virus 3 from 3 patients, and RSV from 2 patients. One
patient each had coinfection with CMV, Pseudomonas aeruginosa,
Staphylococcus aureus, and Streptococcus pneumoniae.
Death occurred in all but 1 patient; 3 patients died within
1 month of onset of respiratory illness, and 4 patients died
within 3 months of the onset of illness. The mean time between
illness onset and death was 54 days (median, 23 days; range,
5–143 days). No autopsy data were available from any of these
fatal cases. No relapse of the underlying disease was diagnosed
in any of the patients who died.
DISCUSSION
Our findings indicate that the detection of HRV in the BAL
fluid of HSCT recipients with pneumonia is associated with a
high mortality rate and frequent coinfection. This suggests that
HRV could cause lower respiratory tract disease in highly im-
munosuppressed HSCT recipients. In addition, the present
study demonstrates the importance of using RT-PCR—the
most sensitive available technique for diagnosing HRV infec-
tions—in this patient population, because cell culture results
may be insensitive unless specific efforts are taken to isolate
rhinoviruses [2, 26].
Respiratory viruses have been increasingly recognized to be
associated with severe respiratory complications in immuno-
suppressed HSCT recipients [27]. The present study provides
additional evidence that HRV can be associated with life-threat-
ening lower respiratory tract disease in such patients. HRV RNA
was detected in 8% of patients who had a bronchoscopy with
BAL for an acute pulmonary infiltrate. Half of the HRV-positive
patients died during the first month after infection, and, ul-
timately, 5 of 6 died. However, all of the patients with HRV
had coinfection with at least 1 other pathogen that is likewise
associated with increased mortality in this population. It is
unclear from the available information which agent, the HRV
or the copathogen, was the primary cause of death in these
patients. It is also not clear from these data whether rhinovirus
by itself can cause lower respiratory tract disease. It is of interest
that 2 of 6 patients identified appeared to show persistent HRV
infection. These patients may have had more-compromised
immunity that predisposed them to polymicrobial infections
and a higher risk of infectious mortality. The frequency of
coinfections suggests that HRV may predispose patients to ad-
ditional infections, possibly through an immunomodulatory
mechanism, as has been demonstrated with RSV and parain-
fluenza virus [21, 28] and indicated in vitro for HRV [29].
More data are needed to confirm this hypothesis.
We found that most patients presented with HRV infection
after the first 100 days after transplantation, which is consistent
with a community acquisition of infection. In contrast, Ghosh
et al. [19] reported that all their patients presented with in-
fection within the first 10 days after transplantation, which is
indicative of nosocomial acquisition. Strict infection-control
practices—including the screening of symptomatic patients, in-
stituting early isolation and cohorting, the universal use of
gloves and masks for all contact with symptomatic patients,
strict implementation of hand washing, and restricting staff and
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visitors with upper respiratory symptoms and children aged
!12 years from visiting patients—have been in place for the
past 10 years at FHCRC and may have contributed to reduced
risk of nosocomial HRV infections, particularly early after
transplantation. In addition, our study took place after the
institution of a policy that prohibited staff with uncontrolled
respiratory secretions from having patient contact, which could
have further limited the spread of HRV and coronavirus. It is
also possible that earlier symptoms, restricted to the URT, may
have been missed. Most studies, however, have suggested a
rapid progression to lower airway involvement, if it occurs. As
a result, it is unlikely that these patients were infected for a
long period prior to their BALs. Future studies should do pro-
spective viral cultures of the upper airways to get a better sense
of the epidemiology of respiratory viruses in this population.
There are several limitations to the present study. It was
conducted during a single season at a single center and thus
may not be representative of HRV infections in different areas
of the country or with different viruses that may not have
circulated during our study period. All the samples were de-
tected in patients who had been concurrently diagnosed with
pneumonia by chest radiograph. As a result, the study focused
on patients with severe disease and does not provide data on
the overall incidence of HRV infections in HSCT recipients.
The selection of patients with pneumonia probably overesti-
mates the risk of mortality secondary to HRV infection and
gives no indication of the frequency of progression from upper
airway disease to lower airway disease. A prior report by Bow-
den [4] in HSCT recipients suggested that this risk is low.
There is the possibility that HRV may have been introduced
into the lower respiratory tract during the bronchoscopy pro-
cedure in patients who had URT infection. Unfortunately, we
could not test this possibility by PCR, because no upper respir-
atory samples were saved. In this context, earlier studies per-
formed mainly with CMV may be instructive. Those studies
demonstrated that patients with documented CMV shedding
in the throat often have negative BAL for CMV [30, 31]. Thus,
viral shedding in the throat is not necessarily associated with
lower respiratory tract contamination of the virus when opti-
mized bronchoscopy techniques are used.
Intervention studies are also needed to identify the optimal
way to mange these infections. Capsid-binding (pleconaril) and
3C protease (ruprintrivir) HRV inhibitors are currently under
investigation for the treatment and prevention of HRV infec-
tions in immunocompetent patients, and these agents could be
tested to see whether they favorably affect the clinical course
of complicated HRV infections in HSCT recipients. Pleconaril
is currently available via a compassionate-use program for the
management of HRV in immunocompromised hosts, and there
has been one report [32] of a bone marrow transplant recipient
with a possible rhinovirus pneumonia who was successfully
treated, with pleconaril, as part of this program.
In conclusion, the present study suggests that HRV infection
may sometimes be associated with severe lower respiratory tract
disease and pneumonia in HSCT recipients. Further studies are
needed to determine whether HRV causes lytic infection or acts
primarily via an indirect immunosuppressive effect, resulting
in an increased predisposition to superinfections. In addition,
studies are needed to better clarify the epidemiology of HRV
infection in HSCT recipients and to better understand the risk
factors for progression of HRV URT infections into the lower
respiratory tract. A prospective surveillance study in which all
HSCT recipients with upper or lower respiratory symptoms
have URT and, as possible, lower respiratory tract samples col-
lected to assess the presence of HRV and human coronavirus
by PCR would be needed to delineate the true epidemiology
of these respiratory viral diseases in this population. Such a
prospective study is ongoing.
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